Created by potrace 1.16, written by Peter Selinger 2001-2019
beatandraise
beta
Latest Financials
Filings:
By Category
By Date
Search Filings
Institutional Holders
beta
Earnings Transcripts
beta
Global Search
Company Exhibits:
Indentures
Material Contracts & Credit Agreements
Plans of Reorganization
Articles and Bylaws
Underwriting Agreements
SEC Edgar
ANGIODYNAMICS INC
SIC 3841 · Surgical & Medical Instruments & Apparatus
Support
about
terms
Created by potrace 1.16, written by Peter Selinger 2001-2019
beatandraise.com
Created by potrace 1.16, written by Peter Selinger 2001-2019
beatandraise.com
beta
Latest Financials
Filings:
Category
Date
Search Filings
Institutional Holders
beta
Earnings Transcripts
beta
Global Search
SEC Edgar
ANGIODYNAMICS INC
SIC 3841 · Surgical & Medical Instruments & Apparatus
Support
about
terms
Created by potrace 1.16, written by Peter Selinger 2001-2019
beatandraise.com
beta
Latest Financials
Filings:
Category
Date
Search Filings
Institutional Holders
beta
Earnings Transcripts
beta
Global Search
SEC Edgar
ANGIODYNAMICS INC
SIC 3841 · Surgical & Medical Instruments & Apparatus
Support
about
terms
$
ANGO
ANGIODYNAMICS INC
CIK:
0001275187
|
SEC Filings
Income Statement
Cash Flow
Balance Sheet
v3.26.3
Consolidated Statements of Operations - USD ($)
$ in Thousands
3 Months Ended
Aug. 31, 2026
Aug. 31, 2025
Income Statement [Abstract]
Net sales
$ 80,915
$ 75,711
Cost of sales (exclusive of intangible amortization)
32,875
33,854
Gross margin
48,040
41,857
Operating expenses:
Research and development
7,979
6,417
Sales and marketing
29,986
28,130
General and administrative
12,467
12,555
Amortization of intangibles
2,729
2,653
Acquisition, restructuring and other items, net
2,181
2,758
Total operating expenses
55,342
52,513
Operating loss
(7,302)
(10,656)
Other income (expense):
Interest expense, net
(88)
(4)
Other income (expense), net
94
(178)
Total other income (expense), net
6
(182)
Loss before income tax (benefit) expense
(7,296)
(10,838)
Income tax (benefit) expense
(199)
65
Net loss
$ (7,097)
$ (10,903)
Loss per share
Loss per share, basic (USD per share)
$ (0.17)
$ (0.26)
Loss per share, diluted (USD per share)
$ (0.17)
$ (0.26)
Weighted average shares outstanding
Basic weighted average shares outstanding (in shares)
42,022,000
41,174,000
Diluted weighted average shares outstanding (in shares)
42,022,000
41,174,000
v3.26.3
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
3 Months Ended
Aug. 31, 2026
Aug. 31, 2025
Cash flows from operating activities:
Net loss
$ (7,097)
$ (10,903)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization
5,498
5,950
Non-cash lease expense
366
445
Non-cash interest expense
72
70
Stock based compensation
4,502
4,470
Deferred income taxes
(306)
(16)
Change in accounts receivable allowances
(57)
108
Fixed and intangible asset disposals
81
(27)
Other
(707)
264
Changes in operating assets and liabilities:
Accounts receivable
3,471
139
Inventories
(2,715)
(192)
Prepaid expenses and other
(1,019)
(5,525)
Accounts payable, accrued and other liabilities
(17,419)
(10,697)
Net cash used in operating activities
(15,330)
(15,914)
Cash flows from investing activities:
Additions to property, plant and equipment
(379)
(731)
Additions to placement and evaluation units
(2,769)
(820)
Net cash used in investing activities
(3,148)
(1,551)
Cash flows from financing activities:
Principal payments on financing arrangement
(99)
(91)
Proceeds (outlays) from issuances of shares of common stock
(1,276)
234
Net cash (used in) provided by financing activities
(1,375)
143
Effect of exchange rate changes on cash
(38)
191
Decrease in cash
(19,891)
(17,131)
Cash at beginning of period
53,864
55,893
Cash at end of period
33,973
38,762
Supplemental disclosure of non-cash investing and financing activities:
Accrual for capital expenditures incurred during the period
$ (11)
$ (94)
v3.26.3
Consolidated Balance Sheets - USD ($)
$ in Thousands
Aug. 31, 2026
May 31, 2026
Current assets
Cash
$ 33,973
$ 53,864
Accounts receivable, net of allowances of $1,739 and $1,851 respectively
44,905
48,325
Inventories
54,953
52,436
Prepaid expenses and other
9,172
8,769
Total current assets
143,003
163,394
Property, plant and equipment, net
27,728
27,097
Intangible assets, net
61,894
67,209
Other assets
9,308
9,463
Total assets
241,933
267,163
Current liabilities
Accounts payable
26,579
31,513
Accrued liabilities
28,811
38,909
Other current liabilities
4,299
4,295
Total current liabilities
59,689
74,717
Deferred income taxes
4,680
5,316
Other long-term liabilities
13,601
16,305
Total liabilities
77,970
96,338
Commitments and contingencies (Note 14)
Stockholders' equity
Preferred stock, par value $0.01 per share, 5,000,000 shares authorized; no shares issued and outstanding
0
0
Common stock, par value $0.01 per share, 75,000,000 shares authorized; 43,038,297 and 42,314,266 shares issued and 42,424,450 and 41,700,419 shares outstanding at August 31, 2026 and May 31, 2026, respectively
388
387
Additional paid-in capital
639,308
636,083
Accumulated deficit
(473,036)
(465,939)
Treasury stock, 613,847 shares, at cost at August 31, 2026 and May 31, 2026, respectively
(7,381)
(7,381)
Accumulated other comprehensive income
4,684
7,675
Total Stockholders’ Equity
163,963
170,825
Total Liabilities and Stockholders' Equity
$ 241,933
$ 267,163
Treasury stock, shares (in shares)
613,847
613,847